Search

everythinglearnresearchcommunity

for

Search:↓

Inhibiting certain proteins harms hair follicle immunity and increases IL-33, affecting hair health.

EGFR and MEK inhibitors reduce PD-L1 in hair follicles, possibly causing inflammation.

Erlotinib can cause significant but temporary hair loss in lung cancer patients.

Gefitinib can cause slower, finer, brittle, and curly scalp hair.

Combining ficlatuzumab and gefitinib can cause severe scarring hair loss.

Erlotinib can cause hair loss as a side effect.

Gefitinib therapy can cause unusual hair growth on the nose.

Doxycycline helps prevent skin issues from erlotinib in lung cancer patients.

EGFR inhibitors for lung cancer can cause severe skin issues.

ZD1839 can cause skin issues like acne and hair changes.

Lung cancer biology differs between women and men, with women responding better to certain treatments.

The platform effectively grows lung cancer cell spheroids for drug testing.

EGFR inhibitors often cause skin problems and other side effects, but these are usually reversible and can be managed to keep patients comfortable.

Skin side effects from EGFR inhibitor cancer treatment can be managed effectively, often without stopping the medication.

Some lung cancer patients treated with EGFR inhibitors may develop a hair loss condition similar to folliculitis decalvans.

EGFR cancer drugs often cause a rash, which can lead to distress and isolation, but may also improve outcomes for some cancer patients. Current treatments for the rash are limited, but a compound called menadione shows promise.

Aumolertinib is effective and well-tolerated for treating advanced lung cancer with EGFR mutations.

Excessive eyelash growth from erlotinib may indicate positive tumor response and help treat madarosis.

EGFR inhibitors often cause skin issues like acne and dryness, which can be managed with specific treatments.

Y27632 increases cell growth through EGFR signaling, not ROCK1/2.

EGFR inhibitors can cause yellowish skin eruptions.

Genetic testing for EGFR mutations is crucial in similar cases.

EGFR inhibitors can cause unusual localized hair growth.

Some drugs, especially biologics, can cause skin reactions that look like other skin diseases, and stopping the drug usually helps clear up these reactions.

A cancer patient developed a type of hair loss after starting a cancer drug called vandetanib.

Erlotinib causes skin inflammation through IL-1, which can be reduced by anakinra.

EGF receptor is crucial for skin health and its inhibitors can cause skin rashes.

An 84-year-old man developed a rare scalp condition from a cancer drug but continued treatment as it was otherwise well tolerated.

Dacomitinib can cause nail and skin issues, but these can be managed without stopping the drug.

EGFR inhibitors often cause dry, brittle hair and eyebrow/eyelash changes.